Core LaboratoriesCLB
CLB
About: Core Laboratories is the premier provider of reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
Employees: 3,600
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
391% more call options, than puts
Call options by funds: $2.69M | Put options by funds: $548K
3% less funds holding
Funds holding: 195 [Q2] → 189 (-6) [Q3]
4.11% less ownership
Funds ownership: 112.57% [Q2] → 108.47% (-4.11%) [Q3]
12% less capital invested
Capital invested by funds: $1.07B [Q2] → $943M (-$128M) [Q3]
14% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 71
17% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 35
100% less funds holding in top 10
Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$14
17%
downside
Avg. target
$14
17%
downside
High target
$14
17%
downside
1 analyst rating
0 positive
0%
0 neutral
0%
1 negative
100%
Citigroup Scott Gruber 41% 1-year accuracy 27 / 66 met price target | 17%downside $14 | Sell Maintained | 31 Oct 2024 |
Financial journalist opinion
Based on 3 articles about CLB published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
Clinical Chemistry and Immunoassay Industry Forecast Report to 2028: Integrated and Scalable Core Lab Solutions Driving Transformational Growth
Dublin, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The "Clinical Chemistry and Immunoassay Industry, Global, 2023-2028" report has been added to ResearchAndMarkets.com's offering. This analysis examines the global clinical chemistry and immunoassay sector, accounting for the highest share in the in vitro diagnostics (IVD) market. This type of lab-based testing analyzes body fluids (usually blood, urine, or saliva) using integrated/standalone analyzers and a wide range of assays/panels, among other solutions and services to support the diagnosis and treatment of human health. While clinical chemistry instruments and tests target different chemicals in body fluids to evaluate health and the clinical management of patients, immunoassay instruments and tests measure the presence or concentration of analytes in biological liquid by using the binding of antibodies to antigens to identify and measure certain substances. This competitive analysis examines IVD companies that provide a broad menu of clinical chemistry and immunoassay systems, including instruments and consumables.
Neutral
Zacks Investment Research
1 week ago
Is Now the Right Time to Buy Core Laboratories After Its 12% YTD Rise?
CLB shows strong earnings growth, solid cash flow and innovative technologies, but faces risks from geopolitical tensions, weak U.S. onshore activity and oil price volatility.
Positive
Zacks Investment Research
4 weeks ago
Why Is Core Laboratories (CLB) Up 11.5% Since Last Earnings Report?
Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock?
Neutral
Zacks Investment Research
1 month ago
Is the Options Market Predicting a Spike in CORE LABS INC (CLB) Stock?
Investors need to pay close attention to CORE LABS INC (CLB) stock based on the movements in the options market lately.
Neutral
Seeking Alpha
1 month ago
Core Laboratories Inc. (CLB) Q3 2024 Earnings Call Transcript
Core Laboratories Inc. (NYSE:CLB ) Q3 2024 Earnings Conference Call October 24, 2024 8:30 AM ET Company Participants Larry Bruno - Chairman and Chief Executive Officer Chris Hill - Chief Financial Officer Gwen Gresham - Senior Vice President and Head, Investor Relations Conference Call Participants Sean Mitchell - Daniel Energy Partners Stephen Gengaro - Stifel Operator Good day and welcome to the Core Lab Q3 2024 Earnings Conference Call. All participants will be in a listen-only mode.
Positive
Zacks Investment Research
1 month ago
Core Laboratories' Q3 Earnings and Sales Beat Estimates
CLB expects Reservoir Description revenues of $87.5-$90.5 million and Production Enhancement revenues of $41-$45 million for the fourth quarter of 2024.
Positive
Zacks Investment Research
1 month ago
Core Laboratories (CLB) Q3 Earnings Match Estimates
Core Laboratories (CLB) came out with quarterly earnings of $0.25 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.22 per share a year ago.
Neutral
PRNewsWire
1 month ago
CORE LAB REPORTS THIRD QUARTER 2024 RESULTS
THIRD QUARTER REVENUE OF $134.4 MILLION, UP 3% SEQUENTIALLY AND OVER 7% YEAR-OVER-YEAR THIRD QUARTER OPERATING INCOME OF $19.8 MILLION; EX-ITEMS, $18.2 MILLION, UP 11% SEQUENTIALLY AND 14% YEAR-OVER-YEAR THIRD QUARTER OPERATING MARGINS, EX-ITEMS, OF 14% UP 100 BPS SEQUENTIALLY THIRD QUARTER GAAP EPS OF $0.25; EX-ITEMS, $0.25, UP 14% SEQUENTIALLY AND YEAR-OVER-YEAR THIRD QUARTER FREE CASH FLOW OF $10.4 MILLION NET DEBT REDUCED BY $11.8 MILLION; DEBT LEVERAGE RATIO REDUCED TO 1.47 COMPANY ANNOUNCES Q4 2024 QUARTERLY DIVIDEND HOUSTON , Oct. 23, 2024 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported third quarter 2024 revenue of $134,400,000. Core's operating income was $19,800,000, with diluted earnings per share ("EPS") of $0.25, all in accordance with U.S. generally accepted accounting principles ("GAAP").
Positive
Zacks Investment Research
1 month ago
Energy Stocks to Watch Amid Q3 Earnings Despite Pricing Pressures
Energy stocks such as PUMP, CLB and OII are poised to deliver a Q3 earnings beat.
Neutral
Zacks Investment Research
2 months ago
What's in Store for Core Laboratories Stock in Q3 Earnings?
CLB is expected to report higher revenues compared with the previous quarter, along with reduced costs for services and product sales and general administrative expenses.
Charts implemented using Lightweight Charts™